Clinical trial

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

NCT05559164

Study summary

ClinicalTrials.gov

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Lipitor 40mg Tablet Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-09-19

PhasePHASE2

Conditions

Cardiac Toxicityunresolved

Early-stage Breast Cancerunresolved

Interventions

Lipitor 40mg TabletDRUG

Sponsors & collaborators

Rutgers, The State University of New Jerseylead sponsor

Mapped research locations

New BrunswickNew Jersey, United States2 Long BranchNew Jersey, United States2 NewarkNew Jersey, United States1 HamiltonNew Jersey, United States1 ElizabethNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05559164 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.